CN111819177B - 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 - Google Patents

一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN111819177B
CN111819177B CN201980013553.1A CN201980013553A CN111819177B CN 111819177 B CN111819177 B CN 111819177B CN 201980013553 A CN201980013553 A CN 201980013553A CN 111819177 B CN111819177 B CN 111819177B
Authority
CN
China
Prior art keywords
compound
formula
crystal form
numbering
twenty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980013553.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN111819177A (zh
Inventor
熊剑
陈小新
王晶晶
刘卓伟
陈新海
刘呈武
谢程
龙超峰
李鹏
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of CN111819177A publication Critical patent/CN111819177A/zh
Application granted granted Critical
Publication of CN111819177B publication Critical patent/CN111819177B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980013553.1A 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法 Active CN111819177B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101806418 2018-03-05
CN201810180641 2018-03-05
PCT/CN2019/076916 WO2019170067A1 (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN111819177A CN111819177A (zh) 2020-10-23
CN111819177B true CN111819177B (zh) 2022-03-04

Family

ID=67846865

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980013553.1A Active CN111819177B (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Country Status (11)

Country Link
US (1) US11535613B2 (cg-RX-API-DMAC7.html)
EP (1) EP3763713A4 (cg-RX-API-DMAC7.html)
JP (1) JP7031002B2 (cg-RX-API-DMAC7.html)
KR (1) KR102484804B1 (cg-RX-API-DMAC7.html)
CN (1) CN111819177B (cg-RX-API-DMAC7.html)
AU (1) AU2019230497B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092315C (cg-RX-API-DMAC7.html)
NZ (1) NZ767352A (cg-RX-API-DMAC7.html)
RU (1) RU2769050C1 (cg-RX-API-DMAC7.html)
TW (1) TWI794433B (cg-RX-API-DMAC7.html)
WO (1) WO2019170067A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237212A1 (zh) * 2024-05-11 2025-11-20 广东众生睿创生物科技有限公司 一种嘧啶衍生物葡甲胺盐及其晶型
US12649747B2 (en) 2021-02-03 2026-06-09 Ocumension Therapeutics (Suzhou) Co., Ltd Salt form and crystal form of pyrazole substituted imidazo[1,2-a]quinoxaline derivative

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
JP2024509939A (ja) * 2021-03-11 2024-03-05 シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド ピリジン窒素酸化物の結晶形態およびその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018041263A1 (zh) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20207129B (en) * 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
MX341342B (es) * 2011-01-14 2016-08-17 Vertex Pharma Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
EA201790266A1 (ru) 2014-08-08 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Индолы для применения при инфекции, вызванной вирусом гриппа
JP7129339B2 (ja) * 2016-03-07 2022-09-01 ハイテック パワー,インコーポレーテッド 内燃エンジン用第2燃料を発生させかつ分配する方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492381A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2017097234A1 (en) * 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018041263A1 (zh) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649747B2 (en) 2021-02-03 2026-06-09 Ocumension Therapeutics (Suzhou) Co., Ltd Salt form and crystal form of pyrazole substituted imidazo[1,2-a]quinoxaline derivative
WO2025237212A1 (zh) * 2024-05-11 2025-11-20 广东众生睿创生物科技有限公司 一种嘧啶衍生物葡甲胺盐及其晶型

Also Published As

Publication number Publication date
AU2019230497A1 (en) 2020-09-17
EP3763713A1 (en) 2021-01-13
KR102484804B1 (ko) 2023-01-04
JP7031002B2 (ja) 2022-03-07
TWI794433B (zh) 2023-03-01
US11535613B2 (en) 2022-12-27
NZ767352A (en) 2023-05-26
WO2019170067A1 (zh) 2019-09-12
CA3092315A1 (en) 2019-09-12
CN111819177A (zh) 2020-10-23
EP3763713A4 (en) 2021-11-24
RU2769050C1 (ru) 2022-03-28
KR20200124710A (ko) 2020-11-03
AU2019230497B2 (en) 2021-08-05
CA3092315C (en) 2023-08-29
TW201938558A (zh) 2019-10-01
JP2021514967A (ja) 2021-06-17
US20200407354A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
TWI794433B (zh) 吡啶并吡唑類化合物的晶型、鹽型及其製備方法
CN113260613B (zh) 一种egfr抑制剂的盐、晶型及其制备方法
JP6302906B2 (ja) ウイルス感染および他の疾患を治療するためのアルキルピリミジン誘導体
KR102064807B1 (ko) 바이러스 감염을 치료하기 위한 피페리디노-피리미딘 유도체
KR102225233B1 (ko) 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
EP2978429B1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
ES2680146T3 (es) Hidrocloruro de rilpivirina
EP3992192B1 (en) Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
JP2016518457A (ja) ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
HK40030970B (en) Crystal form and salt form of pyridoimidazole compound and preparation method therefor
CN116323593A (zh) 一种嘧啶衍生物的晶型及其制备方法
CN102276433A (zh) 木豆素c及其衍生物及其在制备抗癌药物中的应用
HK40030970A (en) Crystal form and salt form of pyridoimidazole compound and preparation method therefor
CN102702116B (zh) 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
EP4471017A1 (en) Cyclic(alkyl)(amino)alkoxy-substituted aryl-pyrone compound and use thereof
CN104803877B (zh) 一种o‑苯乙酰‑(4‑三氟甲基)水杨酰胺类化合物及其应用
HK1207636B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40030970

Country of ref document: HK

CB02 Change of applicant information

Address after: 510700 Room 501, building D, 288 Shenzhou Road, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: Guangdong Raynovent Biotech Co.,Ltd.

Address before: 518000 No.3, 3rd floor, phase I, comprehensive Xinxing, No.1 Haihong Road, Fubao community, Fubao street, Futian District, Shenzhen City, Guangdong Province

Applicant before: Guangdong Raynovent Biotech Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant